The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy.

Howard Hughes Medical Institute, Department of Biochemistry & Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6148, USA.
Molecular and Cellular Biology (Impact Factor: 5.04). 08/2005; 25(13):5543-51. DOI: 10.1128/MCB.25.13.5543-5551.2005
Source: PubMed

ABSTRACT Reduction of the survival of motor neurons (SMN) protein levels causes the motor neuron degenerative disease spinal muscular atrophy, the severity of which correlates with the extent of reduction in SMN. SMN, together with Gemins 2 to 7, forms a complex that functions in the assembly of small nuclear ribonucleoprotein particles (snRNPs). Complete depletion of the SMN complex from cell extracts abolishes snRNP assembly, the formation of heptameric Sm cores on snRNAs. However, what effect, if any, reduction of SMN protein levels, as occurs in spinal muscular atrophy patients, has on the capacity of cells to produce snRNPs is not known. To address this, we developed a sensitive and quantitative assay for snRNP assembly, the formation of high-salt- and heparin-resistant stable Sm cores, that is strictly dependent on the SMN complex. We show that the extent of Sm core assembly is directly proportional to the amount of SMN protein in cell extracts. Consistent with this, pulse-labeling experiments demonstrate a significant reduction in the rate of snRNP biogenesis in low-SMN cells. Furthermore, extracts of cells from spinal muscular atrophy patients have a lower capacity for snRNP assembly that corresponds directly to the reduced amount of SMN. Thus, SMN determines the capacity for snRNP biogenesis, and our findings provide evidence for a measurable deficiency in a biochemical activity in cells from patients with spinal muscular atrophy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The motor neuron degenerative disease spinal muscular atrophy (SMA) remains one of the most frequently inherited causes of infant mortality. Afflicted patients loose the survival motor neuron 1 (SMN1) gene but retain one or more copies of SMN2, a homolog that is incorrectly spliced. Primary treatment strategies for SMA aim at boosting SMN protein levels, which are insufficient in patients. SMN is known to partner with a set of diverse proteins collectively known as GEMINs to form a macromolecular complex. The SMN-GEMINs complex is indispensible for chaperoning the assembly of small nuclear ribonucleoproteins (snRNPs), which are key for pre-mRNA splicing. Pharmaceutics that alleviate the neuromuscular phenotype by restoring the fundamental function of SMN without augmenting its levels are also crucial in the development of an effective treatment. Their use as an adjunct therapy is predicted to enhance benefit to patients. Inspired by the surprising discovery revealing a premier role for GEMINs in snRNP biogenesis together with in vivo studies documenting their requirement for the correct function of the motor system, this review speculates on whether GEMINs constitute valid targets for SMA therapeutic development.
    Frontiers in Neuroscience 10/2014; 8:325. DOI:10.3389/fnins.2014.00325
  • [Show abstract] [Hide abstract]
    ABSTRACT: Survival motor neuron protein (SMN) plays essential roles in cell viability and stress responses in higher eukaryotes. However, little is known about the orthologs in fungi except for the only studied yeast SMN. Here, we identified an S MN-like gene in M agnaporthe o ryzae (MOS). Bioinformatics and Southern blot confirmed that MOS is a single copy located on M. oryzae chromosome. But it was detected to contain three transcript isoforms according to RT-PCR identification. Expression patterns of these transcripts revealed that MOS is associated with stress response and conidiogenesis process in M. oryzae. Disruption mutant and its complemented strain (ΔMOS, ΔMOS/MOS) were genetically created in this study. Through biological comparison, we found that ΔMOS, with no more phenotypic defects except for reduced pigmentation and conidiation, was sensitive to oxidative, osmotic, and nitrogen or carbon-starved stresses, suggesting MOS is required for environmental adaption and basic metabolism. Infection assay further indicated MOS contributed to the development of rice blast. Therefore, we suggest that MOS as a pathogenic gene may be a potential target for reducing disease and implications in crop protection.
    European Journal of Plant Pathology 01/2015; DOI:10.1007/s10658-015-0623-x · 1.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The RNA-binding protein FUS/TLS, mutation in which is causative of the fatal motor neuron disease amyotrophic lateral sclerosis (ALS), is demonstrated to directly bind to the U1-snRNP and SMN complexes. ALS-causative mutations in FUS/TLS are shown to abnormally enhance their interaction with SMN and dysregulate its function, including loss of Gems and altered levels of small nuclear RNAs. The same mutants are found to have reduced association with U1-snRNP. Correspondingly, global RNA analysis reveals a mutant-dependent loss of splicing activity, with ALS-linked mutants failing to reverse changes caused by loss of wild-type FUS/TLS. Furthermore, a common FUS/TLS mutant-associated RNA splicing signature is identified in ALS patient fibroblasts. Taken together, these studies establish potentially converging disease mechanisms in ALS and spinal muscular atrophy, with ALS-causative mutants acquiring properties representing both gain (dysregulation of SMN) and loss (reduced RNA processing mediated by U1-snRNP) of function.
    Nature Communications 01/2015; 6:6171. DOI:10.1038/ncomms7171 · 10.74 Impact Factor


Available from